Navigation Links
Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
Date:6/2/2008

- Observed Dose-Response Trends Suggest Improved Efficacy with Higher Doses

-

- Dose Escalation Ongoing -

SAN FRANCISCO and CHICAGO, June 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist, MDV3100, showed encouraging anti-tumor activity as measured by declining serum levels of prostate specific antigen (PSA) and circulating tumor cells (CTC), as well as radiographic disease stabilization, after three months of treatment. An increased number of androgen receptors present on prostate cancer cells is believed to play a major role in the growth of castration-resistant prostate cancer, also known as hormone-refractory prostate cancer. The observed clinical effects of MDV3100 on PSA levels, CTC counts and radiographic disease are consistent with blockade of androgen receptor signaling and inhibition of tumor growth. To date, 90 patients have been enrolled in the trial with enrollment completed at doses up to 240 mg/day. MDV3100 has been well tolerated and dose escalation at 360 mg/day is in progress.

The data were presented at the American Society of Clinical Oncology 2008 Annual Meeting in Chicago in an oral presentation entitled "Phase 1-2 study of MDV3100 in patients (pts) with progressive Castration-Resistant Prostate Cancer (CRPC)" by principal investigator, Howard Scher, M.D., chief of the Genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center in New York.

The ongoing Phase 1-2 trial is an open-label U.S. dose-escalation study enrolling prostate cancer patients
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
2. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
5. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
7. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
8. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
9. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
10. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
11. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  Net Medical Xpress Solutions, Inc., (OTC ... today the company has signed a letter of intent ... in Huntsville, AL . MedTel Solutions ... staffing and recruitment of telemedicine physicians. Consideration for the ... agreement, which is expected by June 30, 2013. ...
(Date:5/23/2013)... -- Israel Brain Technologies (IBT) has announced the ... 1 st International Brain Technology Conference, which ... in Tel Aviv , recently ranked as ... by the Wall Street Journal and the epicenter ... showcase the latest breakthroughs in neuroscience and brain technology and ...
(Date:5/23/2013)... 2013  Datameer announced today that Cardinal Health ... on their big data platform. Datameer gives Cardinal ... to quickly and easily visualize and understand data ... 19 company, Cardinal Health is one of the ... and medical products to more than 60,000 locations ...
Breaking Medicine Technology:Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3Cardinal Health Selects Datameer for Healthcare Data Discovery 2
... SNY ) announced today that it has submitted ... ) in an all-cash transaction valued at approximately $18.5 billion. ... Genzyme shareholders would receive $69 per Genzyme share in cash, ... $49.86 on July 1, 2010. Sanofi-aventis, offer also represents a ...
... Inc. Magazine/Inc.com selects online retail company PainReliever.com (Pain Relievers, ... in the United States. PainReliever.com is owned by Norris ... that a store from Norris E-Commerce Management has won ... was awarded as an Inc. 5000 recipient. ...
Cached Medicine Technology:Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme 2Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme 3Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme 4Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme 5Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme 6Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme 7Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme 8PainReliever.com Earns Inc. 5000 Award 2
(Date:5/23/2013)... Ill. (May 23, 2013) Aortic arch pulse wave ... independent predictor of disease of the vessels that supply ... published in the June issue the journal Radiology ... arch provides functional information about vessel compliance that may ... the road," said Kevin S. King, M.D., assistant professor ...
(Date:5/23/2013)... Elegance for a woman takes on so many different styles. ... can often be found in the mystery of her eyes. It ... through her eyes. It is also true that that her ... the elegance of a woman can be found in her precise ... any other time, utilize eyewear to not only compliment but to ...
(Date:5/23/2013)... Los Angeles, CA (PRWEB) May 23, 2013 ... showcasing the most innovative and stylish eco-friendly hybrids and electric ... savored than in Los Angeles, the symbolic green car capital. ... annual Green Car Tour ride and drive back to ... modern design event. , During the first two days ...
(Date:5/23/2013)... neuroblastoma a common tumor that forms in the nerve ... A study published by Cell Press in the May ... a new genomic approach to screen for compounds that ... differentiate, or convert from immature cells to more specialized ... a compound that causes neuroblastoma cells to differentiate, uncovering ...
(Date:5/23/2013)... Diabetes is one of the worst diseases ... when patients are unfortunate enough to become victims of ... Information Clearinghouse at http://goo.gl/QyhCz , about 60-70 percent ... neuropathy which further shrivels the nervous system and causes ... nerve damage affects the whole body instead of just ...
Breaking Medicine News(10 mins):Health News:MRI-based measurement helps predict vascular disease in the brain 2Health News:Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc. 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 3Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 4Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 5Health News:New screening approach uncovers potential alternative drug therapies for neuroblastoma 2Health News:Neuropathy Nerve Damage Can Now Be Reversed With Neuracel 2
... April 2009, the US District Court for the District ... restraining order, barring Apotex (Apotex, Inc. and Apotex Corp.) ... until further order of the court. On 27 ... determine whether the injunction should be continued.On 30 March ...
... the highlights of the annual meeting of the American ... TV quiz shows. , Like a quiz show, Neurobowl ... subtracts points for wrong answers. The tougher the question, ... to diagnose perplexing neurological conditions, based on symptoms, video ...
... ANDOVER, Mass., April 16 JAZD Markets, the leader in ... announced that it has recently added SEO/SEM veteran Eric Melin ... team to optimize the directory verticals and report directly to ... SEO Guru in Eric Melin , JAZD is ...
... many people out of work, each day, thousands of new ... to this, FDP Inc. has assembled a directory website to ... With average waiting times of one to three years ... and take any job they can find. But, with fewer ...
... Calif., April 16 The California Dental ... deadline is rapidly approaching to have your kindergartener receive ... 2009-10 school year.The requirement has been in effect for ... common chronic childhood disease, it is essential that children ...
... MedInsights, Inc. , a leading provider of ... VIIAD,s award-winning Health Ticket technology ... to adopt VIIAD,s Health Ticket.The MedInsights Care Ticket, powered ... that goes beyond a traditional group health card and ...
Cached Medicine News:Health News:Court Grants AstraZeneca Temporary Restraining Order Against Apotex in PULMICORT RESPULES Patent Litigation 2Health News:What do neurologists do for entertainment? 2Health News:JAZD Adds Search Marketing & SEO Executive Eric Melin as VP, Traffic Generation Team 2Health News:Social Security Attorney Directory Helps to Speed SSDI Benefits 2Health News:California Dental Association Reminds Parents of Kindergarten Dental Check-Up Requirement 2Health News:National Managed Care Provider First to Workers' Compensation Market with Innovative Technology that Reduces Costs to Employers 2
... ( RIFA:) test for the ... serum IgM antibodies to Epstein-Barr ... kit contains ten 12-well slides ... antigen, FITC IgM RIFA: conjugate, ...
... battery-powered, micro-controlled, noninvasive bone growth stimulator indicated ... lumbar spinal fusion surgery for one or ... shown in pre-clinical studies to help the ... studies have also shown that individuals who ...
... adjunctive treatment alternative in the treatment of ... the appendicular system. , Overview , ... leading provider of bone growth stimulators , ... or adjunct to surgery , Indicated for ...
... surgically implanted bone growth stimulator for the ... surgically implanted bone growth stimulator is a ... when surgery is already planned or when ... the OsteoGen is totally surgically implanted, patients ...
Medicine Products: